Lates News

date
03/04/2026
According to AI Express, Huaxin Securities issued a research report on April 3, giving Lianyin Biosciences (002166.SZ) a "buy" rating. The main reasons for the rating include: 1) The decline in gross margin, cost increases, and depreciation amortization; 2) Steady growth in natural sweeteners, good performance of tea extracts; 3) Smooth progress in synthetic biology business, smooth progress in formula applications. (Daily Economic News)
Latest
See all latestmore